Nutriband responds to fentanyl weapon of mass destruction designation

Nutriband Inc. (NASDAQ: NTRB) issued a statement distinguishing between prescription and illicit fentanyl following the Trump Administration's executive order designating illicit fentanyl and its precursor chemicals as weapons of mass destruction.

The Orlando-based company emphasized that FDA-approved prescription fentanyl therapies, including transdermal patches, should not be conflated with illegally manufactured fentanyl. The company stated these prescription products are produced under regulatory oversight and serve patients with severe chronic pain.

Nutriband is developing Aversa Fentanyl, an abuse-deterrent fentanyl transdermal system that combines the company's proprietary technology with Kindeva's FDA-approved fentanyl patch. The product aims to deter abuse and reduce accidental exposure risks while maintaining access for patients requiring opioid treatment.

According to the company, transdermal fentanyl patch abuse and accidental pediatric exposures remain serious problems resulting in medical complications and deaths. FDA-approved transdermal fentanyl patches are indicated for pain management in opioid-tolerant patients requiring daily, long-term treatment when alternative options are inadequate.

The Aversa technology incorporates aversive agents into transdermal patches to prevent abuse, misuse and accidental exposure. Nutriband estimates the product could reach peak annual U.S. sales of $80 million to $200 million, citing a 2022 Health Advances market analysis report.

The company's abuse-deterrent technology is protected by patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico and Australia.

You May Also Be Interested In

• Mesoblast draws $50M from five-year facility to retire existing debt
• UL Solutions opens automotive EMC lab in Toyota City, Japan
• Berenberg Starts Ithaca Energy (ITH:LN) at Buy